6617.TWO Gongwin Biopharm Holdings Co. Ltd.
- Market cap
- TWD 9.21B
- P/E
- -
- P/B
- 5.57x
- ROE
- -7.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6617.TWO undervalued?
Graham numberThe Graham number of Gongwin Biopharm Holdings Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gongwin Biopharm Holdings Co. Ltd. fundamental analysis
No fundamental analysis for Gongwin Biopharm Holdings Co. Ltd. yet.
Gongwin Biopharm Holdings Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gongwin Biopharm Holdings Co. Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural…
Full company profileGongwin Biopharm Holdings Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gongwin Biopharm Holdings Co. Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.14M | 1.14M | 18.9M | 32.0M | 36.4M | 44.3M |
| Gross Profit | 1.08M | 1.07M | 11.2M | 8.68M | 26.1M | 24.7M |
| Operating Income | -121M | -261M | -133M | -156M | -209M | -235M |
| EBITDA | - | -276M | -80.7M | -76.0M | -104M | -163M |
| Net Income | -122M | -254M | -92.0M | -82.5M | -114M | -164M |
| EPS | -1.09 | -2.25 | -0.81 | -0.65 | -0.93 | -1.35 |
| Balance Sheet | ||||||
| Total Assets | 1.17B | 1.62B | 1.52B | 3.38B | 2.80B | 2.64B |
| Total Liabilities | 184M | 249M | 204M | 282M | 279M | 317M |
| Shareholders' Equity | 971M | 1.39B | 1.32B | 3.11B | 2.53B | 2.33B |
| Cash & Short-term Investments | 454M | 672M | 274M | 893M | 969M | 766M |
| Cash Flow | ||||||
| Operating Cash Flow | -95.5M | -232M | -111M | -87.4M | -136M | -202M |
| Capital Expenditure | 54.0K | 6.17M | 1.13M | 206M | 2.46M | 3.13M |
| Free Cash Flow | -95.6M | -238M | -112M | -294M | -138M | -205M |
| Ratios | ||||||
| ROE | -12.5% | -18.3% | -7.0% | -2.7% | -4.5% | -7.0% |
| ROA | -10.4% | -15.7% | -6.1% | -2.4% | -4.1% | -6.2% |
| Net Profit Margin | -10,637.0% | -22,238.8% | -486.6% | -257.6% | -313.1% | -370.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gongwin Biopharm Holdings Co. Ltd. dividends
Gongwin Biopharm Holdings Co. Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Gongwin Biopharm Holdings Co. Ltd.
- Insiders 53.33%
- Institutions 0.04%
- Public & others 46.63%
- Shares outstanding 121M
- Free float 53.6M
Gongwin Biopharm Holdings Co. Ltd. company profile
- Company name
- Gongwin Biopharm Holdings Co. Ltd.
- Ticker
- 6617.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 80, Jianguo North Road, Taipei, Taiwan, 10491
- Phone
- 886 2 2503 5282
- Website
- gongwinbiopharm.com
About Gongwin Biopharm Holdings Co. Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co. Ltd. management
6- Mr. Chonghan Wu Ph.D.Founder & Chairman · born 1966
- Mr. Mao-Yuan LinGM & Director · born 1961
- Chang En WangAssistant Manager of Marketing Division
- Rocky ShihCo-Founder
- Mr. Wei Nan HuCFO, Accounting Director & Head of Administration Division
- Mr. Quan-Qing YangDeputy General Manager